Trials / Completed
CompletedNCT00149877
Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 250 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a new class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study is to investigate the efficacy, safety and tolerability of tegaserod on bowel habits in patients with CC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegaserod |
Timeline
- Start date
- 2004-04-01
- Completion
- 2006-02-01
- First posted
- 2005-09-08
- Last updated
- 2008-02-01
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00149877. Inclusion in this directory is not an endorsement.